Agios is committed to building the leading portfolio of treatments based on insights into cellularmetabolism and precision medicine – fields in which we believe we are poised to delivermultiple novel treatments with the potential to change patients’ lives.
Agios is actively seeking potential collaboration or licensing opportunities that would complement our existing portfolio.
If you are interested in partnering with Agios, please contact us at .
In May 2016, Agios and Celgene, a leading biotechnology company, created a new global strategic collaboration focused on metabolic immuno-oncology, an emerging field of cancer research focused on altering the metabolic state of immune cells to enhance the body’s immune response to cancer. The goal of the collaboration is to discover, develop and commercialize novel immuno-oncology therapies based on Agios' innovative cellular metabolism research platform.
In October 2016, Agios announced collaboration agreements with Abbott, a leader in diagnostic technologies, to develop and commercialize companion diagnostic tests on Abbott’s m2000 RealTime System to identify isocitrate dehydrogenase (IDH) mutations in acute myeloid leukemia (AML) patients. Celgene is currently developing enasidenib (AG-221/CC-90007), an IDH2 mutant inhibitor, for the treatment of patients with relapsed or refractory AML who have an IDH2 mutation. Agios is developing Ivosidenib, an IDH1 mutant inhibitor, for the treatment of patients with relapsed or refractory AML who have an IDH1 mutation. Celgene and Agios have entered into separate agreements with Abbott to develop diagnostic tests to identify IDH2 and IDH1 mutations, respectively.
In March 2013, Agios entered into a multi-year diagnostic partnership with Foundation Medicine for Agios’ lead programs in cancer metabolism. These programs focus on developing new cancer metabolism inhibitors targeting tumors carrying mutations in either the IDH1 or IDH2 metabolic enzymes. Foundation Medicine and Agios are collaborating to identify tumor genomic alterations that can be used to identify which patients are most likely to respond to Agios’ IDH1 and IDH2 investigational medicines.